Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC -4.27%57 Cash Ratio is 4.98 as of Mar. 2026, which is 117% above its 10-year median of 2.30. GuruFocus rates BGLC with a GF Score™ of 57/100 and a GF Value™ of $2.14 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,579 Chemicals companies, BioNexus Gene Lab ranks better than 94.17% on this metric.
BioNexus Gene Lab has a Cash Ratio of 4.98. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for BioNexus Gene Lab's Cash Ratio or its related term are showing as below:
BGLC'
s Cash Ratio Range Over the Past 10 Years
Min: 0.58 Med: 2.3 Max: 20
Current: 4.98
During the past 8 years, BioNexus Gene Lab's highest Cash Ratio was 20.00. The lowest was 0.58. And the median was 2.30.
BGLC's Cash Ratio is ranked better than 94.17% of 1579
companies
in the Chemicals industry
Industry Median: 0.5
vs BGLC: 4.98
BioNexus Gene Lab (NAS:BGLC) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
BioNexus Gene Lab Cash Ratio Related Terms
BioNexus Gene Lab Cash Ratio Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Cash Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Cash Ratio distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Cash Ratio of 4.98 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioNexus Gene Lab and its competitors. This is 117% above median its historical median of 2.30. Over the past decade, BioNexus Gene Lab's Cash Ratio has ranged from 0.58 to 20.00. According to the industry distribution chart, BioNexus Gene Lab ranks #92 out of 1579 companies in the Chemicals industry, placing it in the top 5.8%.
Is BioNexus Gene Lab's Cash Ratio too high?
BioNexus Gene Lab's current Cash Ratio of 4.98 is 117% above median its 10-year median of 2.30. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 20.00. The Chemicals industry median Cash Ratio is 0.50. BioNexus Gene Lab's value of 4.98 is 896% above this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #92 out of 1579 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Cash Ratio compare to VYST and QGAI?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #92 out of 1579 companies for Cash Ratio. This places BioNexus Gene Lab in the top 6% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.50. BioNexus Gene Lab's value of 4.98 is 896% above this benchmark. Historically, BioNexus Gene Lab's own Cash Ratio has ranged from 0.58 to 20.00 over the past decade. While the company's 10-year median is 2.30 vs. the industry median of 0.50, BioNexus Gene Lab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Chemicals company?
The median Cash Ratio among Chemicals companies is 0.50, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Cash Ratio of 4.98 is 896% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Cash Ratio is 0.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Cash Ratio is 4.98, which is 117% above median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.14, compared to a current price of $1.57 — trading 26.6% below its estimated fair value. The current Cash Ratio is 4.98, which is 117% above median its 10-year median of 2.30 and 896% above the Chemicals industry median of 0.50. BioNexus Gene Lab's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Cash Ratio is 4.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.57 is trading 26.6% below its estimated GF Value™ of $2.14.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Cash Ratio: 4.98 (117% above median its 10-year median of 2.30)
GF Value™: $2.14 vs. price of $1.57 (26.6% below fair value)
Industry Position: 896% above the Chemicals median (#92 of 1579)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
57GF Score
Get the complete analysis for BGLC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
